AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 32 min read$KMTS

Webster Brian Daniel sold $692K of KMTS

Webster Brian Daniel (See Remarks) sold 29,822 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $23.21 ($22.60–$23.92, $0.69M total) across 3 trades over 2026-07-30 to 2026-08-03.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Aug 3, 2026, 11:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may influence sentiment, but it does not introduce new operational, financial, or regulatory information about KMTS.

02

Market read

Traders may monitor KMTS for any clustering of insider sales or abnormal trading activity, but the filing alone is unlikely to drive a sustained move.

03

What to watch

The article does not disclose total insider holdings changes beyond the post-transaction share count, nor does it provide context on prior sales frequency or whether other insiders sold concurrently.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-03 after-hours, covering sales from 2026-07-30 to 2026-08-03

Background

The article is an SEC Form 4 insider transaction filing for Kestera Medical Technologies, Ltd. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows officer/director Webster Brian Daniel sold 29,822 KMTS shares for about $692K across three trades (7/30-8/3).

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on selling or unusual volume rather than expecting a durable repricing.

Evidence & confidence

The filing is a primary-source Form 4, but it provides no new company fundamentals, guidance, or transaction terms beyond the sale size and timing.

Market effects

Sector

No sector-level implications; this is company-specific insider transaction reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for diversification or liquidity needs; absence of a stated 10b5-1 plan does not automatically imply negative fundamentals.

Key entities

  • issuer
    KMTS

    Kestra Medical Technologies, Ltd., the company whose insider transaction is reported.

  • insider
    Webster Brian Daniel

    Officer and director who sold 29,822 shares in open-market transactions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min
SEP 14
$KMTSHigh

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported

SEC EDGAR 8-K2 min